Key points are not available for this paper at this time.
Elinzanetant led to a significantly lower frequency of vasomotor symptoms associated with endocrine therapy than placebo. (Funded by Bayer; OASIS-4 ClinicalTrials.gov number, NCT05587296.).
Building similarity graph...
Analyzing shared references across papers
Loading...
Fátima Cardoso
Brighton and Sussex Medical School
Susanne Parke
Bayer (Germany)
Donal J. Brennan
University College Dublin
New England Journal of Medicine
Imperial College London
Charité - Universitätsmedizin Berlin
University of Liverpool
Building similarity graph...
Analyzing shared references across papers
Loading...
Cardoso et al. (Mon,) studied this question.
synapsesocial.com/papers/69dcc97a7873f5f05b134159 — DOI: https://doi.org/10.1056/nejmoa2415566